Raghavan S, Ho YL, Kini V, et al. – In a cohort of US adults with diabetes, researchers conducted explored the connections between early systolic blood pressure (SBP) treatment and atherosclerotic cardiovascular disease (ASCVD) events (fatal and nonfatal myocardial infarction and stroke). Between 2002 and 2007, researchers assessed 43,986 patients with diabetes who newly initiated antihypertensive therapy. At treatment initiation (130–139 or ≥ 140 mmHg) and after 2 years of treatment (100–119, 120–129, 130–139, 140–159, and ≥ 160 mmHg), patients were classified into categories based on SBP. According to findings, patients with diabetes who initiated antihypertensive therapy with SBP 130–139 mmHg and those with SBP < 130 mmHg on-treatment had better results than those with greater SBP levels when initiating or after 2 years of treatment.